A recent study found that toxicity is routinely minimized in phase 3 oncology trials, especially those that are not industry sponsored.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback